RATIONALE: Methamphetamine (MA) dependence accounts for substantial neuropsychiatric morbidity. Furthermore, there is evidence in the literature of psychiatric and cognitive impairment in chronic users. OBJECTIVES: This report compares the general psychiatric and cognitive functioning, including impulsive decision-making, of individuals dependent on MA and normal controls. MATERIALS AND METHODS: Forty-one currently abstinent individuals in treatment for MA dependence and 41 controls participated. Controls were selected to minimize group differences in age and gender. MA users met DSM-IV criteria for MA dependence, had average daily use of 0.5 g/day (0.5-6 g/day), had been abstinent at least 2 weeks (2-24 weeks), and did not currently meet criteria for other Axis I psychiatric disorders. Psychiatric symptoms were rated on standardized scales. Cognitive function was assessed with a battery of standardized neuropsychological tests. Impulsivity was assessed using a delay discounting task, which measured preference for small, immediate, and large delayed rewards. RESULTS: The MA group reported more psychiatric symptoms than controls, and was impaired relative to controls on the Babcock Story Recall-Delayed and the Rey Auditory Verbal Learning Test. MA-dependent subjects discounted delayed rewards more than controls, and this measure of impulsivity was correlated with memory impairment in the MA group but not in the controls. CONCLUSIONS: MA-dependent individuals are more impulsive than controls, and this may be causally related to memory deficits but was unrelated to any other measure of psychiatric or cognitive impairment or any drug use history variable.
RATIONALE: Methamphetamine (MA) dependence accounts for substantial neuropsychiatric morbidity. Furthermore, there is evidence in the literature of psychiatric and cognitive impairment in chronic users. OBJECTIVES: This report compares the general psychiatric and cognitive functioning, including impulsive decision-making, of individuals dependent on MA and normal controls. MATERIALS AND METHODS: Forty-one currently abstinent individuals in treatment for MA dependence and 41 controls participated. Controls were selected to minimize group differences in age and gender. MA users met DSM-IV criteria for MA dependence, had average daily use of 0.5 g/day (0.5-6 g/day), had been abstinent at least 2 weeks (2-24 weeks), and did not currently meet criteria for other Axis I psychiatric disorders. Psychiatric symptoms were rated on standardized scales. Cognitive function was assessed with a battery of standardized neuropsychological tests. Impulsivity was assessed using a delay discounting task, which measured preference for small, immediate, and large delayed rewards. RESULTS: The MA group reported more psychiatric symptoms than controls, and was impaired relative to controls on the Babcock Story Recall-Delayed and the Rey Auditory Verbal Learning Test. MA-dependent subjects discounted delayed rewards more than controls, and this measure of impulsivity was correlated with memory impairment in the MA group but not in the controls. CONCLUSIONS: MA-dependent individuals are more impulsive than controls, and this may be causally related to memory deficits but was unrelated to any other measure of psychiatric or cognitive impairment or any drug use history variable.
Authors: Jennifer L Perry; Erin B Larson; Jonathan P German; Gregory J Madden; Marilyn E Carroll Journal: Psychopharmacology (Berl) Date: 2004-08-27 Impact factor: 4.530
Authors: Sandra D Comer; Warren K Bickel; Richard Yi; Harriet de Wit; Stephen T Higgins; Galen R Wenger; Chris-Ellyn Johanson; Mary Jeanne Kreek Journal: Behav Pharmacol Date: 2010-07 Impact factor: 2.293
Authors: Kimber L Price; Stacia M DeSantis; Annie N Simpson; Bryan K Tolliver; Aimee L McRae-Clark; Michael E Saladin; Nathaniel L Baker; Mark T Wagner; Kathleen T Brady Journal: Am J Addict Date: 2011-07-18
Authors: Warren K Bickel; Bryan A Jones; Reid D Landes; Darren R Christensen; Lisa Jackson; Michael Mancino Journal: Exp Clin Psychopharmacol Date: 2010-12 Impact factor: 3.157
Authors: Mary-Lynn Brecht; Judith Stein; Elizabeth Evans; Debra A Murphy; Douglas Longshore Journal: J Behav Health Serv Res Date: 2008-01-24 Impact factor: 1.505
Authors: Jordan E Cattie; Steven Paul Woods; Jennifer E Iudicello; Carolina Posada; Igor Grant Journal: J Neuropsychiatry Clin Neurosci Date: 2012 Impact factor: 2.198
Authors: Mehmet Sofuoglu; Andrew J Waters; Marc Mooney; Thomas Kosten Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2007-05-18 Impact factor: 5.067
Authors: Andy C Dean; Edythe D London; Catherine A Sugar; Christina M R Kitchen; Aimee-Noelle Swanson; Keith G Heinzerling; Ari D Kalechstein; Steven Shoptaw Journal: Drug Alcohol Depend Date: 2009-07-15 Impact factor: 4.492
Authors: Donald M Dougherty; Nora E Charles; Charles W Mathias; Stacy R Ryan; Rene L Olvera; Yuanyuan Liang; Ashley Acheson Journal: Drug Alcohol Depend Date: 2014-07-23 Impact factor: 4.492